-
Finland grants licence for world's first nuclear waste repository
-
Canada opens free trade talks with Turkey
-
'Old-fashioned' South Africa thump Australia to level Test series
-
Swiss, Austrian women freed after Niger kidnap ordeal
-
No more taking out the trash at your Airbnb
-
Austrian-born French resistance fighter dies aged 105: regional official
-
Swiss supreme court upholds Guatemala ex-police chief sentence
-
Paris shop-owners and residents prepare for fresh protests
-
UN climate disaster fund moves to provide $20 mn aid for Nepal
-
French, Japanese authors try to write novel on one-day train ride
-
Africa faces 'complex' Ebola outbreak after spread to Nigeria: WHO
-
Pentagon, Lockheed announce agreement for 850 F-35 jets over 10 years
-
American detained in Russia arrives in US: lawyer
-
Brook scores fastest double century in ODI history in rampant England's 429-4
-
Pentagon, Lockheed announce deal for 850 F-35 jets over 10 years
-
Top-ranked Rybakina into Ningbo quarter-finals on return from injury
-
French authorities seek to ban or curb fresh protests
-
Samson superb as India mark record T20 chase in win over New Zealand
-
Nearly all coral reefs risk collapse in 50 years: IUCN
-
Nvidia boss criticises 'cheap' AI doomsday warnings
-
Foden can be one of Premier League's best again, says Maresca
-
Philippines trailblazer Eala ousted in Ningbo last 16
-
'Solution from the heavens': Indonesians pray for rain as fires burn
-
Stocks retreat as tech mood sours, oil prices jump
-
Targeted by Trump, ICC wins top EU rights prize
-
Northern start and finale in the Pyrenees for 2027 Tour de France
-
Grabbing a bargain: Japan's claw machines cash in on inflation
-
Handful of Micron workers strike in Taiwan
-
Barclays bank to cut about 5,000 jobs amid AI drive
-
Zelensky says fresh Russian strikes show 'no change' in Kremlin position
-
Son of Myanmar's Suu Kyi says had first call in five years
-
China slams 'Cold War mentality' after new EU Arctic plan
-
Taiwan issues warnings as Typhoon Champi nears
-
Алекс Боди и ръководителят на BlackRock Лари Финк в Берлин: инвестиции в Германия и Румъния?
-
Alex Bodi és Larry Fink, a BlackRock vezetője Berlinben: befektetések Németországban és Romániában?
-
Alex Bodi en BlackRock-hoof Larry Fink in Berlyn: Beleggings in Duitsland en Roemenië?
-
एलेक्स बोदी और ब्लैकरॉक प्रमुख लैरी फ़िंक बर्लिन में: जर्मनी और रोमानिया में निवेश?
-
Ageing Japanese village turns to Peru in search of new residents
-
Alex Bodi ve BlackRock Başkanı Larry Fink Berlin’de: Almanya ve Romanya’ya yatırım mı?
-
Targeted by Trump, ICC in running for top EU rights prize
-
Wrong anthems played at Asian Para Games after mishap-marred Asian Games
-
Asian stocks retreat as tech mood sours again
-
Thales sales jump on European rearmament, satellite systems
-
Lula seeks tit-for-tat annulment of Bolsonaro election candidacy
-
أليكس بودي ورئيس بلاك روك لاري فينك في برلين: استثمارات في ألمانيا ورومانيا؟
-
אלכס בודי ומנכ״ל בלאקרוק לארי פינק בברלין: השקעות בגרמניה וברומניה?
-
Alex Bodi och BlackRock-chefen Larry Fink i Berlin: investeringar i Tyskland och Rumänien?
-
Alex Bodi și șeful BlackRock, Larry Fink, la Berlin: investiții în Germania și România?
-
Alex Bodi a šéf společnosti BlackRock Larry Fink v Berlíně: Investice v Německu a Rumunsku?
-
Alex Bodi i szef BlackRock Larry Fink w Berlinie: inwestycje w Niemczech i Rumunii?
BioLargo Installs AEC PFAS Treatment System at Lake Stockholm, New Jersey
WESTMINSTER, CALIFORNIA / ACCESS Newswire / January 27, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed at the Lake Stockholm municipal water facility in New Jersey.
BioLargo CEO Dennis Calvert commented, "The Lake Stockholm installation marks an important milestone for BioLargo as its AEC technology transitions into real-life municipal use. Once the facility goes through the commissioning process to get fully operational, this system will provide the Lake Stockholm community with drinking water that exceeds both the EPA's and New Jersey's stricter PFAS drinking water standards."
The Aqueous Electrostatic Concentrator (AEC) is well suited for Lake Stockholm because it can effectively treat both long- and short-chain PFAS, which are present in the source water and are difficult to remove with conventional technologies. And, unlike many treatment options that generate large volumes of contaminated residual waste, the AEC operates with minimal waste-an especially critical advantage for Lake Stockholm, which has no available onsite waste outlet. This makes the AEC a practical, protective solution that improves drinking water quality by removing the PFAS to below state and federal levels, while avoiding the creation of a new disposal problem for the community.
Ongoing testing activities will be conducted in coordination with regulatory oversight from the New Jersey Department of Environmental Protection (NJDEP) and the U.S. Environmental Protection Agency (EPA). Over the next several months data generated during this process will support ongoing regulatory requirements and confirm readiness for sustained municipal service.
"This installation will undergo 12 months of special NJDEP monitoring that includes regular testing for PFAS chemicals. We expect this data can help establish AEC as an industry leading solution that can exceed the toughest PFAS drinking water standards in the country, and to lead to many opportunities in New Jersey and elsewhere," states Tonya Chandler, President of BioLargo Equipment, Solutions and Technologies, Inc. "Our pipeline of interest and opportunities grows daily. The AEC is perfectly designed to scale as utilities seek sustainable, low-waste solutions for comprehensive PFAS removal."
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.
View the original press release on ACCESS Newswire
L.Davis--AMWN